Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Asahina · SciRah

Researcher profile · Semantic Scholar

H. Asahina

Share profile

H. Asahina — researcher profile on SciRah

h-index: 26
Works: 136
Citations: 4,232

Most-cited papers

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
S. Koyama, Esra A. Akbay, Yvonne Y. Li, G. Herter-Sprie +22 more
2016Nature Communications1,466 citations Open access
Semantic Scholar
STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T cell activity in the lung tumor microenvironment
S. Koyama, Esra A. Akbay, Yvonne Y. Li, A. Aref +29 more
2016Cancer Research557 citations Open access
Semantic Scholar
A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors *,†
N. Yamamoto, H. Nokihara, Yasuhide Yamada, Y. Goto +7 more
2012Cancer Science77 citations Open access
Semantic Scholar
Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS
S. Kitajima, H. Asahina, Ting Chen, Su-Juan Guo +21 more
2018Cancer Cell67 citations Open access
Semantic Scholar
Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer.
Yoko Tsukita, T. Tozuka, K. Kushiro, Shinobu Hosokawa +16 more
2024JAMA Oncology66 citations Open access
Semantic Scholar
CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC.
Jeffrey H Becker, Yan-Di Gao, M. Soucheray, I. Pulido +24 more
2019Cancer Research51 citations Open access
Semantic Scholar
A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
H. Asahina, S. Oizumi, K. Takamura, T. Harada +17 more
2019Lung Cancer44 citations Open access
Semantic Scholar
Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
Kentaro Tanaka, H. Asahina, J. Kishimoto, Y. Miyata +10 more
2021European Journal of Cancer41 citations
Semantic Scholar
Phase II Study of Amrubicin Combined with Carboplatin for Thymic Carcinoma and Invasive Thymoma: North Japan Lung Cancer Group Study 0803
A. Inoue, S. Sugawara, M. Harada, Kunihiko Kobayashi +8 more
2014Journal of Thoracic Oncology40 citations Open access
Semantic Scholar
Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study
H. Asahina, H. Nokihara, N. Yamamoto, Yasuhide Yamada +7 more
2013Investigational new drugs36 citations
Semantic Scholar
A phase II study of trastuzumab monotherapy in pretreated patients with non-small cell lung cancers (NSCLCs) harboring HER2 alterations: HOT1303-B trial.
I. Kinoshita, T. Goda, Kana Watanabe, M. Maemondo +11 more
2018Annals of Oncology33 citations Open access
Semantic Scholar
NSCLC Driven by DDR2 Mutation is Sensitive to Dasatinib and JQ1 Combination Therapy
Chun-Xiao Xu, Kevin A. Buczkowski, Yanxi Zhang, H. Asahina +6 more
2015Molecular Cancer Therapeutics32 citations Open access
Semantic Scholar
Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study.
R. Saito, S. Sugawara, R. Ko, Koichi Azuma +14 more
2023European Journal of Cancer30 citations Open access
Semantic Scholar
Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors
K. Honda, N. Yamamoto, H. Nokihara, Yosuke Tamura +6 more
2013Cancer Chemotherapy and Pharmacology30 citations
Semantic Scholar
Endobronchial ultrasonography with a guide sheath in the diagnosis of benign peripheral diseases.
Naofumi Shinagawa, K. Nakano, H. Asahina, E. Kikuchi +5 more
2012Annals of Thoracic Surgery28 citations
Semantic Scholar
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002)
Gaku Yamamoto, H. Asahina, O. Honjo, Toshiyuki Sumi +19 more
2021Scientific Reports26 citations Open access
Semantic Scholar
Real‐world data on the efficacy and safety of immune‐checkpoint inhibitors in elderly patients with non‐small cell lung cancer
Daisuke Morinaga, H. Asahina, Shotaro Ito, O. Honjo +16 more
2023Cancer Medicine24 citations Open access
Semantic Scholar
A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
H. Asahina, Kentaro Tanaka, S. Morita, M. Maemondo +9 more
2020Clinical Lung Cancer20 citations
Semantic Scholar
Response of BRAFV600E-Mutant Lung Adenocarcinoma With Brain Metastasis and Leptomeningeal Dissemination to Dabrafenib Plus Trametinib Treatment.
Gaku Yamamoto, J. Sakakibara-Konishi, Tomoo Ikari, Hidenori Kitai +4 more
2019Journal of Thoracic Oncology11 citations Open access
Semantic Scholar
A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)
Y. Ikezawa, H. Asahina, S. Oizumi, Masahiro Watanabe +15 more
2017Cancer Chemotherapy and Pharmacology11 citations Open access
Semantic Scholar
Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902).
Shotaro Ito, H. Asahina, O. Honjo, Hisashi Tanaka +15 more
2021Lung Cancer10 citations Open access
Semantic Scholar
Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors
S. Nakamichi, H. Nokihara, N. Yamamoto, Yasuhide Yamada +13 more
2015Investigational new drugs10 citations
Semantic Scholar
The Peptide Nucleic Acid-Locked Nucleic Acid Polymerase Chain Reaction Clamp-Based Test for Epidermal Growth Factor Receptor Mutations in Bronchoscopic Cytological Specimens of Non-Small Cell Lung Cancer
N. Yamada, S. Oizumi, H. Asahina, Naofumi Shinagawa +7 more
2012Oncology10 citations Open access
Semantic Scholar
First-line immune checkpoint inhibitors alone or in combination with chemotherapy in real-life elderly patients with advanced non-small cell lung cancer (NEJ057).
Mao Uematsu, Yoko Tsukita, T. Tozuka, K. Kushiro +16 more
2023Journal of Clinical Oncology9 citations
Semantic Scholar
Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non-small cell lung cancer.
H. Mizugaki, S. Oizumi, Y. Fujita, T. Harada +13 more
2021European Journal of Cancer9 citations Open access
Semantic Scholar
A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors
H. Nokihara, N. Yamamoto, Yasuhide Yamada, K. Honda +7 more
2017Japanese Journal of Clinical Oncology9 citations
Semantic Scholar
Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer
Y. Makino, N. Yamamoto, Hitoshi Sato, R. Ando +11 more
2012Cancer Chemotherapy and Pharmacology9 citations
Semantic Scholar
A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small Cell Lung Cancer Study: (NEJ048A/NEXUS).
A. Miyanaga, H. Asahina, Satoshi Watanabe, T. Shukuya +9 more
2023Clinical Lung Cancer8 citations Open access
Semantic Scholar
Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301)
K. Hashimoto, Daisuke Morinaga, H. Asahina, M. Ishidoya +19 more
2024JTO Clinical and Research Reports6 citations Open access
Semantic Scholar
Detection of multiple druggable mutations of lung cancer from cytology specimens by MINtS: An advanced medicine A trial
Kazutaka Fujita, R. Arai, S. Shoji, R. Saito +22 more
2023Cancer Science6 citations Open access
Semantic Scholar
A case of radio-insensitive SMARCA4-deficient thoracic undifferentiated carcinoma with severe right heart failure
Shotaro Ito, H. Asahina, N. Yamaguchi, U. Tomaru +13 more
2021Respiratory Medicine Case Reports6 citations Open access
Semantic Scholar
Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors
Yosuke Tamura, H. Nokihara, K. Honda, Y. Tanabe +6 more
2016Cancer Chemotherapy and Pharmacology6 citations
Semantic Scholar
O3-9-2A PHASE 1 STUDY OF NECITUMUMAB (ANTI-EGFR MONOCLONAL ANTIBODY) IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
H. Nokihara, N. Yamamoto, Yosuke Tamura, Y. Tanabe +6 more
20146 citations Open access
Semantic Scholar
Phase II study of amrubicin (AMR) and carboplatin (CBDCA) for invasive thymoma (IT) and thymic carcinoma (TC): NJLCG0803.
Y. Kawashima, A. Inoue, S. Sugawara, M. Harada +9 more
20136 citations
Semantic Scholar
Risk of bleeding associated with transbronchial biopsy using flexible bronchoscopy in patients with echocardiographic or chest CT evidence of pulmonary hypertension
Y. Takashima, Naofumi Shinagawa, Daisuke Morinaga, J. Nakamura +8 more
2022BMC Pulmonary Medicine5 citations Open access
Semantic Scholar
Temporary Severe Neutropenia during Administration of Atezolizumab: A Novel Case Report
Ryota Kanno, Y. Saito, Y. Takekuma, H. Asahina +1 more
2023Case Reports in Oncology4 citations Open access
Semantic Scholar
Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma
J. Sakakibara-Konishi, Mineyoshi Sato, Michiko Sato, Kohei Kasahara +6 more
2020Respiratory Medicine Case Reports4 citations Open access
Semantic Scholar
Phase I Study of Ono-4538 (BMS-936558), An Anti PD-1 Antibody, in Japanese Patients with Advanced Solid Tumors
N. Yamamoto, Yasuhide Yamada, H. Nokihara, H. Asahina +6 more
20124 citations Open access
Semantic Scholar
Phase I Study of Anti PD-1 Antibody Ono-4538 in Japanese Patients with Advanced Solid Tumors
N. Yamamoto, H. Nokihara, Yasuhide Yamada, H. Asahina +7 more
20124 citations Open access
Semantic Scholar
Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non–small‐cell lung cancer (NEJ056)
M. Furuta, H. Horinouchi, I. Yokota, Teppei Yamaguchi +16 more
2024Cancer Science3 citations Open access
Semantic Scholar
Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.
Y. Kawashima, A. Inoue, S. Sugawara, S. Oizumi +12 more
2014Respiratory Investigation3 citations Open access
Semantic Scholar
Phase 1 Dose-Escalating Study of BMS-754807 in Japanese Patients with Advanced Solid Tumors
Yosuke Tamura, H. Nokihara, N. Yamamoto, H. Wakui +5 more
20123 citations Open access
Semantic Scholar
A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study.
Hiromi Nagashima, T. Fukuhara, Yu Utsumi, A. Suzuki +18 more
2025European Journal of Cancer2 citations Open access
Semantic Scholar
A Phase 2 Study of Osimertinib in Combination With Platinum-Pemetrexed in Patients With Uncommon Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer (NEJ067/OPAL2).
Daisuke Morinaga, M. Furuta, Satoshi Morita, E. Miyauchi +3 more
2025Clinical Lung Cancer2 citations
Semantic Scholar
A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non–small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).
A. Nakamura, R. Saito, R. Ko, Koichi Azuma +14 more
2022Journal of Clinical Oncology2 citations
Semantic Scholar
Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage
T. Shoji, H. Mizugaki, Y. Ikezawa, M. Furuta +10 more
2018Internal medicine2 citations Open access
Semantic Scholar
Phase II study of amrubicin (AMR) combined with carboplatin (CBDCA) for refractory relapsed small cell lung cancer (SCLC): North Japan Lung Cancer Group 0802.
R. Saito, A. Inoue, S. Sugawara, S. Oizumi +11 more
20122 citations
Semantic Scholar
Partial Response to Repotrectinib in ROS1-Rearranged Lung Squamous Cell Carcinoma: A Brief Report.
Yukiko Yoshida, H. Asahina, Ken Kuwahara, H. Mizugaki +5 more
2026Clinical Lung Cancer1 citations
Semantic Scholar
Afatinib Versus Osimertinib for Non‐Small Cell Lung Cancer With Uncommon EGFR Mutations: Real‐World Outcomes
Y. Nagano, H. Yokouchi, Ryota Saito, O. Honjo +18 more
2026Cancer Science1 citations Open access
Semantic Scholar
First Clinical Evidence of Repotrectinib Efficacy in ROS1-Rearranged NSCLC With a D2033N Resistance Mutation: Case Report.
Yukiko Yoshida, H. Yokouchi, H. Mizugaki, N. Yamada +4 more
2025Clinical Lung Cancer1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Oizumi×15
Invite
S. Oizumi — researcher profile on SciRah
N. Yamamoto×11
Invite
N. Yamamoto — researcher profile on SciRah
H. Nokihara×11
Invite
H. Nokihara — researcher profile on SciRah
T. Tamura×11
Invite
T. Tamura — researcher profile on SciRah

Yasuhide Yamada

×10

Invite

Yasuhide Yamada — researcher profile on SciRah

Kunihiko Kobayashi×10

Invite

Kunihiko Kobayashi — researcher profile on SciRah

Invite

E. Kikuchi — researcher profile on SciRah

Invite

M. Maemondo — researcher profile on SciRah

Yosuke Tamura×9

Invite

Yosuke Tamura — researcher profile on SciRah

Invite

K. Honda — researcher profile on SciRah

Invite

T. Harada — researcher profile on SciRah

Invite

H. Mizugaki — researcher profile on SciRah